{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:05Z","timestamp":1790887685352,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40265-017-0802-5","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T10:48:38Z","timestamp":1502966918000},"page":"1603-1610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Inotuzumab Ozogamicin: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"issue":"5","key":"802_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.12862","volume":"98","author":"S Thota","year":"2017","unstructured":"Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425\u201334.","journal-title":"Eur J Haematol"},{"issue":"5","key":"802_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/2040620715596715","volume":"6","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253\u201361.","journal-title":"Ther Adv Hematol."},{"key":"802_CR3","unstructured":"Pfizer. Besponsa approved in the EU for adult patients with relapsed or refractory B-cell percursor acute lymphoblastic leukemia [media release]. 30 Jun 2017. http:\/\/www.pfizer.com\/ ."},{"key":"802_CR4","unstructured":"Pfizer Limited. Besponsa (inotuzumab ozogamicin) 1\u00a0mg powder for concentrate for solution for infusion: summary of product characteristics. 2017. Accessed 21 Jul 2017."},{"issue":"8","key":"802_CR5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"10","key":"802_CR6","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3109\/10428194.2015.1017821","volume":"56","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed\/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10):2863\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"802_CR7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","volume":"174","author":"A Goy","year":"2016","unstructured":"Goy A, Forero A, Wagner-Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571\u201381.","journal-title":"Br J Haematol"},{"key":"802_CR8","unstructured":"European Medicines Agency. Summary of opinion (initial authorisation): Besponsa (inotuzumab ozogamicin). 2017. http:\/\/www.ema.europa.eu\/ . Accessed 21 Jul 2017."},{"key":"802_CR9","unstructured":"Pfizer. Pfizer announces acceptance of regulatory submission for inotuzumab ozogamicin by the U.S. Food and Drug Administration [media release]. 21 Feb 2017. http:\/\/www.pfizer.com\/ ."},{"key":"802_CR10","unstructured":"Celltech Group Plc. Celltech Group plc oncology pipeline update [media release]. 16 Jun 2003. http:\/\/www.celltechgroup.com\/ ."},{"key":"802_CR11","unstructured":"Pfizer, Wyeth. Pfizer completes acquisition of Wyeth [media release]. 16 Oct 2009. http:\/\/www.pfizer.com\/ ."},{"issue":"4","key":"802_CR12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-010-1342-9","volume":"67","author":"JF DiJoseph","year":"2011","unstructured":"DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4):741\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"802_CR13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807\u201314.","journal-title":"Blood"},{"issue":"2","key":"802_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","volume":"26","author":"JF Vries de","year":"2012","unstructured":"de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255\u201364.","journal-title":"Leukemia"},{"issue":"11","key":"802_CR15","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF DiJoseph","year":"2007","unstructured":"DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240\u20135.","journal-title":"Leukemia"},{"issue":"15","key":"802_CR16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017;1(15):1167\u201380.","journal-title":"Blood Adv."},{"issue":"8","key":"802_CR17","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387\u201398.","journal-title":"Lancet Haematol."},{"issue":"Suppl 1","key":"802_CR18","first-page":"S11","volume":"99","author":"M Garrett","year":"2016","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, et al. Characterization of inotuzumab ozogamicin time-dependent clearance in relapsed\/refractory acute lymphoblastic leukemia patients by nonlinear mixed-effects analysis [abstract no. PC-26]. Clin Pharmacol Ther. 2016;99(Suppl 1):S11.","journal-title":"Clin Pharmacol Ther"},{"issue":"15 Suppl","key":"802_CR19","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/JCO.2017.35.15_suppl.7007","volume":"35","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, DeAngelo DJ, Stelljes M, et al. Factors associated with allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in patients (pts) with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) treated with inotuzumab ozogamicin (InO) versus (v) conventional chemotherapy (C) [abstract no. 7007]. J Clin Oncol. 2017;35(15 Suppl):7007.","journal-title":"J Clin Oncol"},{"issue":"22","key":"802_CR20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood.V128.22.1599.1599","volume":"128","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a global phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard of care chemotherapy for relapsed\/refractory acute lymphoblastic leukemia [abstract no. 1599]. Blood. 2016;128(22):1599.","journal-title":"Blood"},{"key":"802_CR21","doi-asserted-by":"crossref","unstructured":"van Oostrum I, Su Y, Heeg B, et al. Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) [abstract no. e18506]. J Clin Oncol. 2017;35(15 Suppl).","DOI":"10.1200\/JCO.2017.35.15_suppl.e18506"},{"issue":"4","key":"802_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403\u201311.","journal-title":"Lancet Oncol."},{"issue":"15","key":"802_CR23","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728\u201336.","journal-title":"Cancer"},{"issue":"2","key":"802_CR24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","volume":"61","author":"M Rytting","year":"2014","unstructured":"Rytting M, Triche L, Thomas D, et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(2):369\u201372.","journal-title":"Pediatr Blood Cancer"},{"issue":"15 Suppl","key":"802_CR25","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1200\/JCO.2017.35.15_suppl.10512","volume":"35","author":"D Bhojwani","year":"2017","unstructured":"Bhojwani D, Sposto R, Shah N, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) [abstract no. 10512]. J Clin Oncol. 2017;35(15 Suppl):10512.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"802_CR26","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/JCO.2017.35.15_suppl.7025","volume":"35","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian HM, Ravandi F, et al. Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R\/R acute lymphoblastic leukemia (ALL) [abstract no. 7025]. J Clin Oncol. 2017;35(15 Suppl):7025.","journal-title":"J Clin Oncol"},{"issue":"22","key":"802_CR27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V128.22.588.588","volume":"128","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, O\u2019Brien SM, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial [abstract no. 588]. Blood. 2016;128(22):588.","journal-title":"Blood"},{"issue":"22","key":"802_CR28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V128.22.1634.1634","volume":"128","author":"AS Advani","year":"2016","unstructured":"Advani AS, Moseley A, Liedtke M, et al. A phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed\/refractory CD22+ acute leukemia (SWOG 1312) [abstract no. 1634]. Blood. 2016;128(22):1634.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0802-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T14:23:05Z","timestamp":1602771785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0802-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0802-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,17]]}}}